# US 12,599,589 B2 · Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,599,589 B2
- Document ID: US12599589B2
- Status: Granted
- Kind: B2
- Application number: 17/788,516
- Filed: 2020-12-24
- Published: 2023-03-30
- Granted: 2026-04-14
- Earliest claimed: 2019-12-25
- Assignees: Nippon Shinyaku Co., Ltd.
- Applicants: Nippon Shinyaku Co., Ltd.
- Inventors: Ken Okamoto; Maki Kurita; Hiroshi Yamaguchi
- Web page: https://patentgrep.com/patent/US12599589B2

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/08: of the prostate
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome, the agent containing an mPGES-1 inhibitor as an active ingredient.

## Claims

### Claim 1

A method for treating chronic prostatitis/chronic pelvic pain syndrome, the method comprising administering an mPGES-1 inhibitor to a subject in need thereof,
wherein the mPGES-1 inhibitor is at least one compound selected from the group consisting of:
N-(3-chloro-2-methylphenyl)-2-(methoxymethyl)-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide, and
N-(3-chloro-2-methylphenyl)-2-[1-(trifluoromethyl)cyclopropyl]-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide, or a tautomer of the compound, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mPGES-1 inhibitor is N-(3-chloro-2-methylphenyl)-2-(methoxymethyl)-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide 4-methylbenzenesulfonate.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the mPGES-1 inhibitor is N-(3-chloro-2-methylphenyl)-2-[1-(trifluoromethyl)cyclopropyl]-6-({[2-(trifluoromethyl)phenyl]carbonyl}amino)-1H-benzimidazole-4-carboxamide.